HighTower Advisors LLC Boosts Holdings in Medpace Holdings, Inc. $MEDP

HighTower Advisors LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 37.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,453 shares of the company’s stock after purchasing an additional 1,476 shares during the period. HighTower Advisors LLC’s holdings in Medpace were worth $3,063,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. NewEdge Advisors LLC increased its holdings in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in Medpace during the 2nd quarter valued at about $296,000. Finally, M&T Bank Corp increased its holdings in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Medpace Price Performance

Medpace stock opened at $447.11 on Friday. Medpace Holdings, Inc. has a 12-month low of $291.28 and a 12-month high of $628.92. The stock has a market capitalization of $12.77 billion, a P/E ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.19. The firm’s 50-day moving average is $457.47 and its two-hundred day moving average is $513.97.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Activity

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 20.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Barclays dropped their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday, February 13th. Robert W. Baird decreased their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.